Fludalanine/pentizadone

D-alanine racemase inhibitor
Merk Sharpe and Dohme Laboratories.
1975

  • Highest development stage: Preclinical

  • Gram-positive activity

  • Gram-negative activity

  • Combination therapy

  • Mechanism of Action/Target pathogen: Cell wall component mimetics.

  • Reason dropped: High levels of patient toxicity.

  • Additional information: 1. Kahan, F. M., and H. Kropp. "MK641/MK642. A fixed-ratio combination antimicrobial. 1 Rationale: The sequential blockade of bacterial cell-wall biosynthesis." Program and Abstracts of the 15th Intersci. Conf. on Antimicrob. Agents Chemother. No. 100. 1975. 2. Wise, R., and J. M. Andrews. "In vitro activity of fludalanine combined with pentizidone compared with those of other agents." Antimicrobial agents and chemotherapy 25.5 (1984): 612-617.

  • GtoPDB link: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10810
  • Compound/Drug Structure: https://pubchem.ncbi.nlm.nih.gov/compound/146933